Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Organigram Global Inc. is a Canadian cannabis company focused on the production and distribution of branded recreational cannabis products and the development of next-generation cannabinoid-based offerings. The company operates primarily within the recreational cannabis, medical cannabis, and cannabis-derived consumer products industries, with an emphasis on regulated markets. Its core revenue is driven by adult-use cannabis sales in Canada, complemented by medical cannabis distribution and international exports.
The company is known for its diversified brand portfolio and its emphasis on product innovation, particularly in inhalable cannabis formats and value-oriented segments. Organigram traces its origins to 2013 as Organigram Inc., evolving through capacity expansions, licensing milestones, and a rebranding to Organigram Global Inc. in 2023 to reflect its broader international ambitions and strategic investments beyond the Canadian market.
Business Operations
Organigram’s operations are structured around cannabis cultivation, product development, manufacturing, and branded sales. Its primary operating segments include Recreational Cannabis, Medical Cannabis, and International and Other revenues. The company generates revenue through wholesale distribution to provincial cannabis boards, direct-to-patient medical sales, and exports to regulated international markets. Its product categories span dried flower, pre-rolls, vapes, edibles, and concentrates.
The company’s principal production asset is its indoor cultivation and manufacturing campus in Moncton, New Brunswick, which integrates automated growing systems and in-house processing technologies. Organigram operates through key subsidiaries including Organigram Inc. and Laurentian Organic Inc., the latter supporting its organic cannabis offerings. Strategic partnerships include a significant equity and commercial relationship with British American Tobacco through its investment arm, supporting product development and research initiatives.
Strategic Position & Investments
Organigram’s strategic direction emphasizes market share growth in Canada’s adult-use cannabis sector while selectively expanding into international and cannabinoid-adjacent opportunities. The company has focused on operational efficiency, brand rationalization, and increased penetration in value and mainstream price segments, which have represented a substantial portion of Canadian consumer demand.
A cornerstone of its strategy is the long-term investment and collaboration with British American Tobacco, which has resulted in multiple tranches of equity investment and the creation of a product development center focused on novel inhalation technologies. Organigram has also invested in emerging cannabinoid research, including rare cannabinoids and biosynthesis, while maintaining optionality for entry into the U.S. market if federal regulations change. Certain future-facing initiatives remain subject to regulatory and market uncertainty.
Geographic Footprint
Organigram is headquartered in Canada, with its corporate headquarters and primary operations located in Moncton, New Brunswick. Its core commercial presence is concentrated across Canadian provinces, where it distributes products through government-run wholesale frameworks and licensed medical channels.
Internationally, the company has established a presence through exports and strategic investments in Europe, Israel, and Australia, primarily serving medical cannabis markets. While international revenue remains a smaller portion of total sales compared to Canada, these activities provide Organigram with regulatory experience and optional expansion pathways in global cannabis markets.
Leadership & Governance
Organigram is led by an executive team with experience in consumer packaged goods, regulated industries, and cannabis operations. The leadership philosophy emphasizes disciplined capital allocation, product-led growth, and long-term shareholder value supported by strategic partnerships and governance oversight.
Key executives include:
- Beena Goldenberg – Chief Executive Officer
- Paolo De Luca – Chief Strategy Officer
- Craig Waddedell – Chief Financial Officer
- Mike Gorenstein – Executive Chairman
- Kurt Schmidt – President
The board of directors includes representatives with backgrounds in finance, consumer products, and regulated industries, including individuals associated with strategic investors, supporting governance aligned with international expansion and compliance-focused growth.